The India Wealth Survey 2025, which surveyed 465 households across 28 cities, revealed that 43% of high-net-worth individuals (HNIs) save less than 20% of their post-tax income, despite aspiring for early retirement, entrepreneurial ventures, and financial stability for their children.
The White Sox said they are still considering building their proposed new ballpark at the South Loop site, potentially creating a new pro sports nexus in Chicago.
Kotak Institutional Equities' Sanjeev Prasad observes the Nifty 50 index is range bound. Valuations are expensive, but macroeconomics are decent. Earnings growth faces challenges from domestic and global issues. Good macroeconomics may not translate to market gains. Commodity sectors and tariff increases drive incremental profits. Earnings upgrades are not visible despite positive macro factors.
Morgan Stanley initiated coverage on Swiggy with an 'Overweight' rating and a price target of Rs 405, indicating a 22% upside. The brokerage highlighted strong growth potential in food delivery and quick commerce, valuing Swiggy as an emerging competitor to market leader Zomato with significant long-term earnings prospects.
Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase 2 trials for psoriasis and atopic dermatitis. The company has decided to discontinue development of the drug. Separately, a surprise FDA inspection is underway at Sun Pharmas Halol manufacturing facility.
